Hepatosplenic T-cell lymphoma and TNF-α inhibitors

Expert Rev Hematol. 2009 Dec;2(6):611-4. doi: 10.1586/ehm.09.62.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Immunosuppression Therapy / adverse effects*
  • Infliximab
  • Liver Neoplasms / mortality
  • Liver Neoplasms / physiopathology*
  • Liver Neoplasms / therapy*
  • Lymphoma, T-Cell / mortality
  • Lymphoma, T-Cell / physiopathology*
  • Lymphoma, T-Cell / therapy*
  • Male
  • Splenic Neoplasms / mortality
  • Splenic Neoplasms / physiopathology*
  • Splenic Neoplasms / therapy*
  • Tumor Necrosis Factor-alpha* / antagonists & inhibitors
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab